ARS Pharmaceuticals' investment thesis is centered on the uncertain commercial trajectory of its product, which has generated erratic quarterly revenue ranging from $2.1M to $86.6M over the past year. The primary concern is the company's massive SG&A expense, ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.63-31.9% vs -$0.48 | $34M+7.5% vs $31M |
Q2 2026 May 15, 2026 | -$0.61-15.1% vs -$0.53 | $23M+2.2% vs $22M |
Q2 2026 Mar 9, 2026 | -$0.42+0.0% vs -$0.42 | $28M+9.7% vs $26M |
Q4 2025 Nov 10, 2025 | -$0.52-15.6% vs -$0.45 | $33M+27.0% vs $26M |
If you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us.
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY PR Newswir
LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Benchmark SPRY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ARS Pharmaceuticals, Inc. (SPRY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.07 | $404.16M | -2.34 | -5.46% | -203.25% | -92.33% | — | |
| $9.72 | $2.25B | 16.20 | 19.63% | 32.98% | 39.59% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $410.35 | $58.77B | -269.97 | 35.9% | -7.11% | -11.73% | — | |
| $3.61 | $403.71M | -3.31 | -18.77% | -12.9% | -8.09% | — | |
| $109.86 | $13.03B | 42.91 | 37.55% | 24.86% | 180.63% | — |
ARS Pharmaceuticals, Inc. (SPRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ARS Pharmaceuticals, Inc. (SPRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 17, 2026·SEC
Jul 7, 2026·SEC
Get notified when SPRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARS Pharmaceuticals, Inc. (SPRY) stock FAQ — growth, dividends, profitability & financials explained
ARS Pharmaceuticals, Inc. (SPRY) reported $116.9M in revenue for fiscal year 2025.
ARS Pharmaceuticals, Inc. (SPRY) saw revenue decline by 5.5% over the past year.
ARS Pharmaceuticals, Inc. (SPRY) reported a net loss of $215.4M for fiscal year 2025.
ARS Pharmaceuticals, Inc. (SPRY) has a return on equity (ROE) of -92.3%. Negative ROE indicates the company is unprofitable.
ARS Pharmaceuticals, Inc. (SPRY) had negative free cash flow of $196.6M in fiscal year 2025, likely due to heavy capital investments.
